Evotec Se Adr Stock Buy Hold or Sell Recommendation
| EVO Stock | USD 3.51 0.12 3.54% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Evotec SE ADR is 'Hold'. The recommendation algorithm takes into account all of Evotec SE's available fundamental, technical, and predictive indicators you will find on this site.
Check out Evotec SE Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Evotec and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Evotec |
Execute Evotec SE Buy or Sell Advice
The Evotec recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Evotec SE ADR. Macroaxis does not own or have any residual interests in Evotec SE ADR or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Evotec SE's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Evotec SE Trading Alerts and Improvement Suggestions
| Evotec SE ADR generated a negative expected return over the last 90 days | |
| Evotec SE ADR has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 781.43 M. Reported Net Loss for the year was (83.91 M) with profit before taxes, overhead, and interest of 106.45 M. | |
| Latest headline from finance.yahoo.com: Introducing Seequent Evo Redefining Geoscience Collaboration and Data Management for Faster and Smarter Decision-Making |
Evotec SE Returns Distribution Density
The distribution of Evotec SE's historical returns is an attempt to chart the uncertainty of Evotec SE's future price movements. The chart of the probability distribution of Evotec SE daily returns describes the distribution of returns around its average expected value. We use Evotec SE ADR price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Evotec SE returns is essential to provide solid investment advice for Evotec SE.
| Mean Return | -0.44 | Value At Risk | -6.1 | Potential Upside | 4.45 | Standard Deviation | 3.54 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Evotec SE historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Evotec Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Evotec SE, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Evotec SE ADR back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Quadrant Capital Group Llc | 2024-12-31 | 5.8 K | Signaturefd, Llc | 2024-12-31 | 3.9 K | Ubs Group Ag | 2024-12-31 | 3.7 K | Optiver Holding B.v. | 2024-12-31 | 2.5 K | Briaud Financial Planning Inc | 2024-12-31 | 2.2 K | Cbiz Investment Advisory Services, Llc | 2024-12-31 | 840 | Lindbrook Capital, Llc | 2024-12-31 | 536 | Advisor Group Holdings, Inc. | 2024-12-31 | 505 | Accent Capital Management Llc | 2024-12-31 | 412 | Mubadala Investment Company Pjsc | 2024-12-31 | 4.6 M | Wellington Management Company Llp | 2024-12-31 | 2.3 M |
Evotec SE Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 145.5M | 276.7M | (284.2M) | 95.8M | 110.1M | 115.6M | |
| Free Cash Flow | (54.4M) | 3.3M | 21.8M | (182.0M) | (179.6M) | (170.6M) | |
| Depreciation | 56.1M | 67.6M | 81.7M | 99.9M | 93.0M | 97.6M | |
| Other Non Cash Items | 6.5M | (171.5M) | 160.2M | 232.3M | 24.4M | 16.3M | |
| Capital Expenditures | 99.1M | 118.9M | 181.4M | 216.0M | 248.4M | 260.8M | |
| Net Income | 6.3M | 215.5M | (175.7M) | (83.9M) | (96.5M) | (91.7M) | |
| End Period Cash Flow | 422.6M | 699.3M | 415.2M | 510.9M | 587.5M | 616.9M | |
| Change To Inventory | (1.4M) | (3.6M) | (11.7M) | (4.4M) | (4.0M) | (3.8M) | |
| Investments | (38.8M) | (117.1M) | (415.8M) | (13.3M) | (12.0M) | (12.6M) | |
| Net Borrowings | (79.3M) | 209.4M | (5.2M) | (5.9M) | (5.3M) | (5.0M) | |
| Change To Netincome | (31.2M) | 24.1M | 19.3M | (158.6M) | (142.7M) | (135.6M) |
Evotec SE Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Evotec SE or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Evotec SE's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Evotec stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 0.63 | |
σ | Overall volatility | 3.67 | |
Ir | Information ratio | -0.09 |
Evotec SE Volatility Alert
Evotec SE ADR exhibits very low volatility with skewness of 0.46 and kurtosis of 2.07. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Evotec SE's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Evotec SE's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Evotec SE Fundamentals Vs Peers
Comparing Evotec SE's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Evotec SE's direct or indirect competition across all of the common fundamentals between Evotec SE and the related equities. This way, we can detect undervalued stocks with similar characteristics as Evotec SE or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Evotec SE's fundamental indicators could also be used in its relative valuation, which is a method of valuing Evotec SE by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Evotec SE to competition |
| Fundamentals | Evotec SE | Peer Average |
| Return On Equity | -0.16 | -0.31 |
| Return On Asset | -0.0177 | -0.14 |
| Profit Margin | (0.22) % | (1.27) % |
| Operating Margin | (0.18) % | (5.51) % |
| Current Valuation | 1.3 B | 16.62 B |
| Shares Outstanding | 355.11 M | 571.82 M |
| Shares Owned By Institutions | 2.52 % | 39.21 % |
| Number Of Shares Shorted | 689.52 K | 4.71 M |
| Price To Earning | 444.00 X | 28.72 X |
| Price To Book | 1.16 X | 9.51 X |
| Price To Sales | 1.55 X | 11.42 X |
| Revenue | 781.43 M | 9.43 B |
| Gross Profit | 106.45 M | 27.38 B |
| EBITDA | 24.12 M | 3.9 B |
| Net Income | (83.91 M) | 570.98 M |
| Cash And Equivalents | 823.67 M | 2.7 B |
| Cash Per Share | 2.33 X | 5.01 X |
| Total Debt | 626.2 M | 5.32 B |
| Debt To Equity | 0.40 % | 48.70 % |
| Current Ratio | 3.21 X | 2.16 X |
| Book Value Per Share | 5.46 X | 1.93 K |
| Cash Flow From Operations | 36.44 M | 971.22 M |
| Short Ratio | 13.14 X | 4.00 X |
| Earnings Per Share | (0.53) X | 3.12 X |
| Price To Earnings To Growth | 3.15 X | 4.89 X |
| Target Price | 7.09 | |
| Number Of Employees | 5.01 K | 18.84 K |
| Beta | 0.96 | -0.15 |
| Market Capitalization | 1.2 B | 19.03 B |
| Total Asset | 2.25 B | 29.47 B |
| Retained Earnings | (476.29 M) | 9.33 B |
| Working Capital | 438.59 M | 1.48 B |
| Five Year Return | 4.88 % |
Note: Acquisition by Bank Of America Corp de of 200 shares of Evotec SE at 12.82 subject to Rule 16b-3 [view details]
Evotec SE Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Evotec . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 2176.25 | |||
| Daily Balance Of Power | 1.714286 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 3.5 | |||
| Day Typical Price | 3.5 | |||
| Price Action Indicator | 0.075 | |||
| Period Momentum Indicator | 0.12 |
About Evotec SE Buy or Sell Advice
When is the right time to buy or sell Evotec SE ADR? Buying financial instruments such as Evotec Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Evotec SE in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Services Thematic Idea Now
Services
Companies involved in delivering services to business or consumers across different industries and sectors. The Services theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Evotec SE Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.53) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets | Return On Equity |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.